RxDoctor Payments Data

Adrienne Briggs, NP

Gerontology · Dover, DENPI 1962120899

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. Reporting peaked in 2024 at $231 and has fallen 78.1% since, to $51 in 2025.

$564in general payments, 2019–2025

Across 20 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$150
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • Novartis$97
  • Abbott$61
  • Pfizer$38
  • Sanofi-aventis U.S. LLC$34
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gerontology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$66,917
Medicare patients
407
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$39,038
JardianceEmpagliflozin20$22,446
XareltoRivaroxaban20$17,795
Rosuvastatin Calcium75$1,661
Atorvastatin Calcium147$1,514
Omeprazole54$879
Hydralazine Hcl29$665
Levothyroxine Sodium57$626
Losartan Potassium49$611
Albuterol Sulfate HfaAlbuterol Sulfate14$592
Metoprolol Succinate55$591
Montelukast Sodium47$566
FenofibrateFenofibrate Nanocrystallized13$496
Gabapentin30$481
Lisinopril43$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$39,03837 claims
Boehringer IngelheimJardiance$17$22,44620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other gerontology in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →